pembrolizumab


( Last Updated : August 4, 2022)
Generic Name:
pembrolizumab
Project Status:
Active
Therapeutic Area:
Triple-negative breast cancer
Manufacturer:
Merck Canada Inc.
Call for patient/clinician input open:
Brand Name:
Keytruda
Project Line:
Reimbursement Review
Project Number:
PC0279-000
Call for patient/clinician input closed:
Tumour Type:
Breast
NOC Status at Filing:
Pre NOC

Details


Manufacturer Requested Reimbursement Criteria1:
Keytruda is indicated for the treatment of adult patients with early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery.
Submission Type:
Initial
Fee Schedule:
Schedule A
Tumour Type:
Breast
Indications:
Keytruda is indicated for the treatment of adult patients with early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery.
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Submit Feedback

Key Milestones2

Call for patient/clinician input open 20-Jan-22
Call for patient/clinician input closed 11-Mar-22
Clarification:

- Patient input submission received from Rethink Breast Cancer and Canadian Breast Cancer Network

Submission received 17-Feb-22
Submission accepted 04-Mar-22
Review initiated 07-Mar-22
Draft CADTH review report(s) provided to sponsor for comment 25-May-22
Deadline for sponsors comments 03-Jun-22
CADTH review report(s) and responses to comments provided to sponsor 30-Jun-22
Expert committee meeting (initial) 13-Jul-22
Draft recommendation issued to sponsor July 25, 2022
To
July 27, 2022
Draft recommendation posted for stakeholder feedback 04-Aug-22
End of feedback period 18-Aug-22